Adalta Ltd (1AD) - Total Assets
Based on the latest financial reports, Adalta Ltd (1AD) holds total assets worth AU$1.85 Million AUD (≈ $1.31 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 1AD operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Adalta Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Adalta Ltd's total assets have evolved over time, based on quarterly financial data. See Adalta Ltd shareholders equity for net asset value and shareholders' equity analysis.
Adalta Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Adalta Ltd's total assets of AU$1.85 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 61.0% |
| Accounts Receivable | AU$835.97K | 39.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Adalta Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Adalta Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adalta Ltd's current assets represent 100.0% of total assets in 2025, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 61.0% of total assets in 2025, down from 98.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 39.0% of total assets.
Adalta Ltd Competitors by Total Assets
Key competitors of Adalta Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Adalta Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.89 | 3.06 | 6.73 |
| Quick Ratio | 0.89 | 3.06 | 6.73 |
| Cash Ratio | 0.00 | 0.00 | 6.51 |
| Working Capital | AU$-218.66K | AU$1.43 Million | AU$7.10 Million |
Adalta Ltd - Advanced Valuation Insights
This section examines the relationship between Adalta Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.40 |
| Latest Market Cap to Assets Ratio | 2.53 |
| Asset Growth Rate (YoY) | -61.6% |
| Total Assets | AU$2.14 Million |
| Market Capitalization | $5.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Adalta Ltd's assets at a significant premium (2.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Adalta Ltd's assets decreased by 61.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adalta Ltd (2012–2025)
The table below shows the annual total assets of Adalta Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.14 Million ≈ $1.52 Million |
-61.57% |
| 2024-06-30 | AU$5.57 Million ≈ $3.94 Million |
-27.93% |
| 2023-06-30 | AU$7.73 Million ≈ $5.47 Million |
-27.38% |
| 2022-06-30 | AU$10.65 Million ≈ $7.53 Million |
+17.67% |
| 2021-06-30 | AU$9.05 Million ≈ $6.40 Million |
+31.01% |
| 2020-06-30 | AU$6.91 Million ≈ $4.89 Million |
-25.81% |
| 2019-06-30 | AU$9.31 Million ≈ $6.59 Million |
+109.73% |
| 2018-06-30 | AU$4.44 Million ≈ $3.14 Million |
-45.13% |
| 2017-06-30 | AU$8.09 Million ≈ $5.72 Million |
-24.60% |
| 2016-06-30 | AU$10.73 Million ≈ $7.59 Million |
+1009.52% |
| 2015-06-30 | AU$967.07K ≈ $684.26K |
+110.34% |
| 2014-06-30 | AU$459.76K ≈ $325.31K |
-24.35% |
| 2013-06-30 | AU$607.75K ≈ $430.02K |
-49.86% |
| 2012-06-30 | AU$1.21 Million ≈ $857.57K |
-- |
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more